BillionToOneBLLN
Recorded

BillionToOne 2026 Stifel Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration32 minParticipants1

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Speaker

Welcome back to the 2026 Stifel Healthcare Conference. We are back on the public side. Happy to have BillionToOne CEO Oguzhan Atay is with us today. Oguzhan, thanks very much for spending some time with us here.

Oguzhan AtayCEO

Thank you for inviting me.

Speaker

Sure. Okay, let's talk a little bit about the business. There are two sides to it. There is a prenatal business and there is an oncology business. Maybe we will start with the oncology business. You have a Northstar Select assay and you have a Northstar Response assay. Those are your two commercial products. They do exist in a crowded market. Liquid biopsy is a field we have followed for a while, and to say the least, there are a lot of players in it. But your products have differentiation that seemingly are yielding a nice ramp here on the assays themselves. The biggest question I get from investors is just how do you compete in this market, just given the nature of it? Maybe you can just spend a second talking about them, talking about why clinicians find them to be useful.

Oguzhan AtayCEO

Certainly. I think these are very crowded markets, as you said, and there are a lot of competitors that are bigger, that are spending more in these markets. But I think we have been able to show, first in prenatal, that you do not have to be spending the most to be able to be successful in a market. You do not have to be the first comer either. You just have to have much better products that you can prove to these providers that they are much better than the existing products. For different products, this can mean something different. For therapy selection, we have been able to show in peer-reviewed studies that compared to incumbents, that we have 50+% higher sensitivity. We can detect 50+% more actionable therapies.

Oguzhan AtayCEO

That is such a high number that it is almost unbelievable, but we actually show it within these clinics as well. If they are currently using a particular product, we can offer them, "Why don't you use our test for five patients, for 10 patients, and to see for yourself that how big of an impact that it can have in their clinical journey?" And once they see it for their patients, they don't just become a user, they become an advocate. I think for Northstar Response monitoring, which this really means being able to detect progression significantly before scans in a tissue-free test. Northstar Response monitoring is an area where I think most people think of as an extension of MRD, minimal residual disease.

Oguzhan AtayCEO

But in many ways, it is a distinct problem. It's a quantitative problem where you are trying to track the tumor burden. It's not a detection problem. And there, I think our technology is so much more powerful than anything that exists. That, I think, has allowed us to show that, especially as the cancer patients, in these late-stage cancer patients, their tumors evolve, the timing is so important that we can not only provide better therapies for them, and that once the cancer evolves and once the patient is no longer responding to therapy, that they can use our response to find that out. But then that also can trigger for them to do another therapy selection test to determine what the second-line therapy is going to be. So there are a lot of interplays between Northstar Select and Northstar Response tests.

Oguzhan AtayCEO

Sometimes they start with doing Northstar Response tests, and then with the progression, they start ordering Northstar Select and see kind of how powerful our Northstar Select test is. Sometimes they start with head-to-head pilot research that they do against whatever test that they might be using in their clinic, see the difference, start with Northstar Select, and then they start adding Northstar Response. But we, in general, see this interplay with Northstar Select and Northstar Response in late-stage cancers. And when we get to MRD, I think that head-to-head, again, starts being very important too.

Oguzhan AtayCEO

Yeah. Right? We are trying to make a claim that they don't believe today.

Oguzhan AtayCEO

We are saying that you can have a tissue-free test that is as performant as tumor-informed assays.

Oguzhan AtayCEO

Today, they have to make that trade-off. Do I use an easier-to-use test that is going to get me the result quickly? Or do I use a test that has a much higher failure rate, that has a much longer turnaround time, and rely on a tumor-informed test that has better sensitivity? What we are telling them is that you don't have to make this trade-off anymore. In response monitoring setting, we have already shown against the most widely used tumor-informed assay that we can actually be not just on par, but more performant than a tumor-informed assay. I think as we show that in the MRD market as well, we are going to have a significant advantage, and we are going to be able to get those providers to adopt our test.

Speaker

Okay. All right. There's a pretty compelling repeat usage or at least longitudinal assessment story. It sounds like it's driven in some cases by response first. I think that's interesting that you start there and then you go to the Northstar Select test. The response assay measures an epigenetic change rather than a variant, a cancer-associated variant. So in some sense, it's different than some of the response monitoring assays that are out there. Is that a distinction without a difference, so to speak? Or is that a clinically meaningful thing that you're doing versus other tests that are trying to monitor for response and resistance?

Oguzhan AtayCEO

I think it can be meaningful, especially if the tumor evolves and you are looking at only particular variants, you might be able to miss that evolution. Whereas when you are looking at an epigenetic change, you can look at much more broadly, because those epigenetic changes happen across the epigenome, whereas the variant changes can be happening in genes that you might not even be assessing.

Speaker

Okay. The confidence that clinicians will appreciate the performance difference is presumably high, because one of the things that we run into, and we realize more and more every day, is that the folks that are thinking about sensitivity of cancer assays, most are guys like me and investors, far more than clinicians. But it sounds like your point is, when these clinicians sort of get into the weeds a little bit and realize what they can do for their patients, that the sensitivity advantage or the performance advantage is what ends up winning the day.

Oguzhan AtayCEO

I think it really depends on how big of a difference that you have. Like a 5% difference is going to be very difficult to convince a physician for. That is why in therapy selection, we are focusing on the sensitivity difference, because we can say that 50% more actionable variants is so significant that you can see the difference in just a few patients. That is not going to be the case when you go into an MRD use case. That is why we are focused there on tissue-free tests, because you need to have almost a categorical difference, that it is much easier to use it as a tissue-free test with the performance of a tumor-informed test, as opposed to kind of saying that we have a more performant tumor-informed test.

Oguzhan AtayCEO

I think the latter is going to be a little bit more difficult to convince physicians, especially in some of the more highly shedding cancer types. I think that starts becoming more meaningful in some of the other cancer types as MRD utilization goes from primarily CRC today to lower and lower shedding cancer types. But today, in CRC, I think that differentiation, as you said, might not be as clinically meaningful. That is why the more meaningful differentiation is that all-important ease of use.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day